The order carried out as a part of the projects titled:
YKL-40: DEVELOPMENT OF A FIRST-IN-CLASS SMALL MOLECULE DRUG CANDIDATE FOR CANCER TREATMENT THROUGH YKL40 INHIBITION (POIR.01.01.01-00-0552/16)
ARG: „PRE-CLINICAL AND CLINICAL DEVELOPMENT OF ARGINASE INHBITOR FOR CANCER IMMUNOTHERAPY” (POIR.01.01.01-00-0415/17)
co-financed by the European Union Funds and because of the competitiveness principle and with the reference to the application process for the grant titled (co-financed by the European Union Funds):
DUBs – RESEARCH AND DEVELOPMENT OF DEUBIQUITINASE INHIBITORS IN ANTITUMOR IMMUNOTHERAPY. We hereby look for Contractor ready to perform the service:
Deliveries of UbiQ substrates within 24 months from the signing of the agreement.